These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26683934)

  • 1. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor.
    Lee YS; Kim H; Kim HW; Lee JC; Paik KH; Kang J; Kim J; Yoon YS; Han HS; Sohn I; Cho J; Hwang JH
    Medicine (Baltimore); 2015 Dec; 94(50):e2224. PubMed ID: 26683934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 4. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
    Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
    Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer.
    Mu YP; Tang S; Sun WJ; Gao WM; Wang M; Su XL
    Asian Pac J Cancer Prev; 2014; 15(20):8893-900. PubMed ID: 25374225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor.
    Hirabayashi K; Tajiri T; Bosch DE; Morimachi M; Miyaoka M; Inomoto C; Nakamura N; Yeh MM
    Pathol Int; 2020 Feb; 70(2):84-91. PubMed ID: 31855317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors.
    Estrella JS; Broaddus RR; Mathews A; Milton DR; Yao JC; Wang H; Rashid A
    Arch Pathol Lab Med; 2014 Aug; 138(8):1027-36. PubMed ID: 25076292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis.
    Kong X; Du Y; Wang G; Gao J; Gong Y; Li L; Zhang Z; Zhu J; Jing Q; Qin Y; Li Z
    Dig Dis Sci; 2011 Feb; 56(2):602-9. PubMed ID: 20614181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
    Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
    Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.